Multiple law firms are investigating The Ensign Group for potential federal securities law violations. These probes follow reports published earlier in June by short-sellers Hunterbrook and Muddy Waters Research.
The reports allege systemic gaming of quality measures and the falsification of care-quality data. They also claim the company committed Medicare and Medicaid fraud.
These allegations caused a significant drop in Ensign's stock price. Investigators are now determining if executives misled investors regarding care quality, regulatory compliance, and growth sustainability.
Marketbeat reported a consensus Moderate Buy rating for the company on June 27, 2026. This rating persists despite several recent changes to analyst recommendations.